In the patients with osteoporosis, bisphosphonates (BPs) are a golden standard treatment. However, the bone turnover markers or the bone mineral density (BMD) are not improved in some osteoporotic patients even though they have taken BPs and alfacalcidol more than several years. In those case, the investigators better off prescribing BPs and Eldecalcitol, instead of BPs and Alfacalcitol.
Alfacalcitol and Eldecalcitol are the similar vitamin D drugs. However, Eldecalcitol is an improved vitamin D drug than Alfacalcitol. Therefore, we investigate the effectiveness of Eldecalcitol in this study.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
100
Edirol 0.5 or 0.75ug once every day oral treatment for at least 1 year after initial visit.
Yukio Nakamura
Matsumoto, Nagano, Japan
RECRUITINGNumber of Participants with bone turnover markers as a Measure of bone quality
Bone formation and bone absorption markers will be evaluated at each time point
Time frame: At 4 months after the initial treatment
Number of Participants with bone turnover markers as a Measure of bone quality
Bone formation and bone absorption markers will be evaluated at each time point
Time frame: At 1 year after the initial treatment
Number of Participants with bone mineral density as a Measure of bone quality
Bone mineral density will be evaluated at each time point
Time frame: At 4 months after the initial treatment
Number of Participants with bone mineral density as a Measure of bone quality
Bone mineral density will be evaluated at each time point
Time frame: At 1 year after the initial treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.